JP2025505687A5 - - Google Patents

Info

Publication number
JP2025505687A5
JP2025505687A5 JP2024547223A JP2024547223A JP2025505687A5 JP 2025505687 A5 JP2025505687 A5 JP 2025505687A5 JP 2024547223 A JP2024547223 A JP 2024547223A JP 2024547223 A JP2024547223 A JP 2024547223A JP 2025505687 A5 JP2025505687 A5 JP 2025505687A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
compound
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/012734 external-priority patent/WO2023154417A1/en
Publication of JP2025505687A publication Critical patent/JP2025505687A/ja
Publication of JP2025505687A5 publication Critical patent/JP2025505687A5/ja
Pending legal-status Critical Current

Links

JP2024547223A 2022-02-09 2023-02-09 Cft7455のモルフィック形態及びその製造方法 Pending JP2025505687A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202210119643.2 2022-02-09
CN202210119643 2022-02-09
US202263308883P 2022-02-10 2022-02-10
US63/308,883 2022-02-10
US202263328659P 2022-04-07 2022-04-07
US63/328,659 2022-04-07
US202363437718P 2023-01-08 2023-01-08
US63/437,718 2023-01-08
PCT/US2023/012734 WO2023154417A1 (en) 2022-02-09 2023-02-09 Morphic forms of cft7455 and methods of manufacture thereof

Publications (2)

Publication Number Publication Date
JP2025505687A JP2025505687A (ja) 2025-02-28
JP2025505687A5 true JP2025505687A5 (cg-RX-API-DMAC7.html) 2026-02-17

Family

ID=87565017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547223A Pending JP2025505687A (ja) 2022-02-09 2023-02-09 Cft7455のモルフィック形態及びその製造方法

Country Status (9)

Country Link
US (1) US20240391912A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476217A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505687A (cg-RX-API-DMAC7.html)
KR (1) KR20240146048A (cg-RX-API-DMAC7.html)
AU (1) AU2023216993A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247460A1 (cg-RX-API-DMAC7.html)
IL (1) IL314625A (cg-RX-API-DMAC7.html)
MX (1) MX2024009897A (cg-RX-API-DMAC7.html)
WO (1) WO2023154417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
KR102947433B1 (ko) * 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6504034B2 (en) * 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
CN111662226B (zh) * 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
KR102947433B1 (ko) * 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
JP7629459B2 (ja) * 2019-11-19 2025-02-13 ブリストル-マイヤーズ スクイブ カンパニー Heliosタンパク質の阻害剤として有用な化合物
AU2021322285B2 (en) * 2020-08-07 2026-08-13 C4 Therapeutics, Inc. Advantageous therapies for disorders mediated by Ikaros or Aiolos
CN118201612A (zh) * 2021-08-04 2024-06-14 上海睿跃生物科技有限公司 用于治疗淋巴瘤的组合疗法的组合物和方法
JP7807110B2 (ja) * 2021-08-27 2026-01-27 ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド イソインドリノン化合物およびその使用

Similar Documents

Publication Publication Date Title
JP2023538520A5 (cg-RX-API-DMAC7.html)
JP3662942B2 (ja) 持続性放出甲状腺作用性組成物
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
JP2024074963A5 (cg-RX-API-DMAC7.html)
JPH06102622B2 (ja) 肥満の治療
JP2022537551A5 (cg-RX-API-DMAC7.html)
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2017525713A5 (cg-RX-API-DMAC7.html)
JP2024517085A5 (cg-RX-API-DMAC7.html)
MX2012013014A (es) Regimenes terapeuticos.
CN110013478A (zh) 用于抗肿瘤试剂施用的方法
RU2007101686A (ru) Комбинированная композиция
JP2008539273A5 (cg-RX-API-DMAC7.html)
Aufdemorte et al. Modified topical steroid therapy for the treatment of oral mucous membrane pemphigoid
JP2024514112A5 (cg-RX-API-DMAC7.html)
MX2026001173A (es) Moduladores del potencial de receptor transitorio melastatina 3 (trpm3) para el tratamiento del dolor
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
JP2021530568A5 (cg-RX-API-DMAC7.html)
US20230414652A1 (en) Composition and therapy for treatment of gag reflexes
JP2023533472A5 (cg-RX-API-DMAC7.html)
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
TWI855501B (zh) 治療方法
Demchuk et al. Therapeutical application of transdermal systems that presented on us pharmaceutical market